AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo

Arundhati Sarkar

• Daiichi Sankyo (DSKYF) and AstraZeneca entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in combination with Summit’s ivonescimab across multiple tumor types, the companies said in a statement on Friday.
• Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
• The companies plan to begin with a phase 3 trial in first-line triple negative breast cancer, the statement said.
• Under the terms of the agreement, each company will contribute their respective compound for the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo.
• AstraZeneca, Daiichi Sankyo and Summit will each contribute to trial costs, and each company will retain development and commercial rights to their respective medicines.

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.